← Leaderboards
Donghoon Chung
University Of Tennessee Health Sci Ctr
$13,304,441
Attributed
$15,612,140
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10M · FY2011–25$20M$15M$10M$5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,612,140 · 6
By mechanism
U19$12,075,966 · 3
R01$3,461,549 · 2
R03$74,625 · 1
Top collaborators
- Jennifer E. Golden5 shared
- Colleen B Jonsson5 shared
- Thomas D Bannister2 shared
- Dahai Luo2 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Colleen B Jonsson$31,118,426
- Elizabeth Ann Fitzpatrick$4,803,552
- Bo Tang$213,502
- Edward F Rosloniec$681,511
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroToxic EffectSeriesAlphavirusLeadViral RnaVenezuelan Equine Encephalitis VirusReplicaseStructurePharmaceutical ChemistryRna Chemical SynthesisHigh Throughput ScreeningAntiviral AgentsWestern Equine Encephalitis VirusResistanceViralCytotoxicityDrug DiscoveryVirusProgramsComplexIn Vitro AssayScaffold
Grant awards (16)
Development of novel antivirals for arthritogenic alphaviruses$544,521
R01 · FY2025 · AI · contact PI
Development of novel antivirals for arthritogenic alphaviruses$140,400
R01 · FY2025 · AI · contact PI
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment$545,850
U19 · FY2023 · AI · contact PI
Project 5: Pandemic Virus Helicase Inhibitors$4,951,273
U19 · FY2022 · AI · contact PI
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment$4,612,067
U19 · FY2022 · AI · contact PI
Project 5: Pandemic Virus Helicase Inhibitors$456,759
U19 · FY2022 · AI · contact PI
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment$476,935
U19 · FY2021 · AI · contact PI
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment$489,811
U19 · FY2020 · AI · contact PI
Lead Optimization of ML336, a Potent VEEV Inhibitor$594,463
R01 · FY2019 · AI · contact PI
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment$543,271
U19 · FY2019 · AI · contact PI
Lead Optimization of ML336, a Potent VEEV Inhibitor$655,453
R01 · FY2018 · AI · contact PI
Lead Optimization of ML336, a Potent VEEV Inhibitor$663,500
R01 · FY2017 · AI · contact PI
Lead Optimization of ML336, a Potent VEEV Inhibitor$415,531
R01 · FY2016 · AI · contact PI
Lead Optimization of ML336, a Potent VEEV Inhibitor$447,681
R01 · FY2015 · AI · contact PI
A Cell-Based HTS to Discover Molecules that Inhibit VEEV Replication$37,375
R03 · FY2012 · MH · contact PI
A Cell-based HTS to discover molecules that inhibit VEEV, encephalitic alphavirus$37,250
R03 · FY2011 · MH · contact PI